Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab as Consolidation Therapy After Concurrent Chemoradiotherapy (cCRT) for Patients With Limited-stage Small-cell Lung Cancer (LS-SCLC): A Retrospective, Single-center, Real-world Cohort Study

NCT07050472 is registered in ClinicalTrials.gov with Anhui Shi, MD as lead sponsor.

NCT NCT07050472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07050472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab as Consolidation Therapy After Concurrent Chemoradiotherapy (cCRT) for Patients With Limited-stage Small-cell Lung Cancer (LS-SCLC): A Retrospective, Single-center, Real-world Cohort Study
Lead sponsor
Anhui Shi, MD
Phase
Observational
Overall status
Completed
Start date
August 11, 2025
Completion date
August 12, 2025
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer